We suggest that LMP1high cells are responsible for the poor drug response of EBV+ DLBCL and that perturbation of the NF-κB and STAT signaling pathways increases toxicity in these cells. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.